Bioequivalence Study of Two Formulations That Contain Isotretinoin 20 mg Capsules in Healthy Colombian Volunteers
![Thumbnail](/themes/unisabana//images/thumbnails/articulos_indexados_item.jpg)
Enlaces del Item
URI: http://hdl.handle.net/10818/36771Visitar enlace: https://www.longdom.org/open-a ...
DOI: 10.4172/jbb.1000308
Compartir
Estadísticas
Ver Estadísticas de usoCatalogación bibliográfica
Mostrar el registro completo del ítemFecha
2016Resumen
This is a pharmacokinetic test of two formulations that contain 20 mg of Isotretinoin, with the aim to compare the
bioavailability between the Test Product (Isoface® from Procaps Laboratory SA, Colombia) and the Reference Product
(Roaccutane® from Catalent Laboratory Germany, Eberbach GMBH, Germany), to declare the bioequivalence
between both formulations. An open, crossed study was developed, randomized, of two periods and two sequences,
with 40 mg single dose of isotretinoin, on fasting conditions, on 24 healthy male Colombian volunteers; the washout
was 14 days in between each period. To present the results, curves of the plasma concentration ratio vs. Time
until hour 72 were performed; with the aim to identify the concentration provided by the Test formulation, the basal
status of each volunteer was eliminated from the analysis, which was built with 3 former concentrations to the test
medicine administration. The analytical method used in this study was high resolution liquid chromatography with
tandem mass spectrometry detector, HPLC MS/MS, for plasma Isotretinoin identification and quantification. The
main pharmacokinetic parameters for the Test Product vs. the Reference Product were Tmáx 2.6 vs. 2.8 h, Cmáx 190.5
vs. 186.5 ng/mL for the AUC0-t 3003.8 vs. 2933.5 h*
ng/mL and AUC0-∞ 3726.3 vs. 3521.2 h*
ng/mL.
The confidence interval calculation of data with logarithmic transformation, showed confidence intervals for
the variables Tmáx, Cmáx, AUCo-t and AUCo-∞, with values between 80-125; values approved by the FDA and EMA
European Medicines Agency, in their Bioavailability and Bioequivalence Guides, to accept the Bioequivalence
hypothesis between the two formulations in study, and thereby declare Bioequivalence and interchange ability of the
Test Product from Procaps Laboratory, with the Reference Product from Roche Laboratory
Ubicación
J Bioequiv Availab 2016, 8:6
Colecciones a las que pertenece
- Facultad de Medicina [957]